A study reported in the Journal of Nuclear Medicine found that F-18 flumazenil PET may be used in place of F-18 FDG PET for localizing the epileptogenic zone in cases of the most common adult form of drug-resistant epilepsy. "F-18 FMZ may provide a different and complementary measure of the epileptogenic substrate to [previous] clinical assessments. Importantly, the F-18 FMZ [binding potential] images could be constructed using a method that did not require arterial blood sampling, making it suitable for routine clinical practice," according to the authors.

Related Summaries